Cargando…

Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways

SIMPLE SUMMARY: Pulmonary sarcomatoid carcinoma (PSC) is an aggressive subtype of non-small-cell lung cancer (NSCLC). It does not respond favorably to standard chemotherapy, and the response to PD-1/PD-L1 inhibitors remains modest. The introduction of new therapeutic approaches for this subtype is c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Feng, Cali Daylan, Ayse Ece, Deng, Lei, Yang, Jihua, Sharma, Janaki, Su, Christopher, Li, Shenduo, Zang, Xingxing, Halmos, Balazs, Borczuk, Alain, Cheng, Haiying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340395/ https://www.ncbi.nlm.nih.gov/pubmed/37444481 http://dx.doi.org/10.3390/cancers15133372

Ejemplares similares

Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail
por: Cali Daylan, Ayse Ece, et al.
Publicado: (2023)

HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival
por: Koirala, Pratistha, et al.
Publicado: (2016)

B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling
por: Rieder, Sadiye Amcaoglu, et al.
Publicado: (2020)

Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma
por: Zhu, Ziwen, et al.
Publicado: (2018)

The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion
por: Hofmeyer, Kimberly A., et al.
Publicado: (2011)

Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer
por: Lv, Chao, et al.
Publicado: (2022)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy
por: Li, Yang, et al.
Publicado: (2022)

HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis
por: Boor, Patrick P. C., et al.
Publicado: (2020)

Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model
por: Chand, Damini, et al.
Publicado: (2019)

PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling
por: Wang, Xiaoqi, et al.
Publicado: (2015)

Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
por: Mienko, Fiona, et al.
Publicado: (2020)

Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma
por: Zhang, Zhen, et al.
Publicado: (2020)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng, Lei, et al.
Publicado: (2018)

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
por: Jing, Chu-Yu, et al.
Publicado: (2019)

Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients
por: Xia, Chao, et al.
Publicado: (2022)

Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities
por: Ren, Xiaoxin, et al.
Publicado: (2021)

Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis
por: Qin, Xiaoyan, et al.
Publicado: (2021)

Corrigendum: Coexpression of HHLA2 and PD-L1 on tumor cells independently predicts the survival of spinal chordoma patients
por: Xia, Chao, et al.
Publicado: (2023)

MEDB-76. Evaluating the B7-H3 checkpoint in Medulloblastoma
por: Moziak, Kirsten, et al.
Publicado: (2022)

Regulation of HHLA2 expression in kidney cancer and myeloid cells
por: Shigemura, Tomonari, et al.
Publicado: (2023)

Correction: Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis
por: Qin, Xiaoyan, et al.
Publicado: (2023)

The B7 family molecules in oral squamous cell carcinoma: a systematic review. Part I: B7-H1 (PD-L1) and B7-DC (PD-L2)
por: Starzyńska, Anna, et al.
Publicado: (2020)

HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
por: Zhou, Qiang-Hua, et al.
Publicado: (2020)

Tissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunity
por: Wei, Joyce, et al.
Publicado: (2011)

B7x and myeloid-derived suppressor cells in the tumor microenvironment: A tale of two cities
por: Jeon, Hyungjun, et al.
Publicado: (2013)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment
por: Luo, Min, et al.
Publicado: (2021)

HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma
por: Xu, Yituo, et al.
Publicado: (2021)

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma
por: Wang, Yuelong, et al.
Publicado: (2020)

Correction: HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
Publicado: (2020)

Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer
por: Yang, Jiayue, et al.
Publicado: (2022)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment [Corrigendum]
Publicado: (2021)

Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer
por: Kula, Agnieszka, et al.
Publicado: (2023)

Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction
por: Wang, Shengdian, et al.
Publicado: (2003)

Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A
por: Pourmaleki, Maryam, et al.
Publicado: (2019)

B7 score and T cell infiltration stratify immune status in prostate cancer
por: Zhou, Qianghua, et al.
Publicado: (2021)

Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy
por: Flies, Dallas B., et al.
Publicado: (2011)

HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
por: Qi, Yangzhi, et al.
Publicado: (2019)

HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer
por: Xu, Guocai, et al.
Publicado: (2021)

HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
por: Qi, Yangzhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_331ipt3pu882eg18rm5nhu4lgv